Bay­er sounds re­treat from a $670 mil­lion CAR-T pact in the wake of a pa­tient death

Two months af­ter Atara Bio­ther­a­peu­tics hit the hold but­ton on its lead CAR-T 2.0 ther­a­py fol­low­ing a pa­tient death, putting the com­pa­ny un­der the watch­ful eye of the FDA, its Big Phar­ma part­ners at Bay­er are bow­ing out of a $670 mil­lion glob­al al­liance. And the move is forc­ing a re­vamp of Atara’s pipeline plans, even as re­search ex­ecs vow to con­tin­ue work on the two drugs al­lied with Bay­er 18 months ago, which de­liv­ered a $60 mil­lion cash up­front.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER